Valuation: Cogent Biosciences, Inc.

Market Cap 6.76B 5.94B 5.55B 5.09B 9.53B 648B 9.76B 65.78B 25.72B 321B 25.39B 24.84B 1,108B P/E 2026 *
-17.3x
P/E 2027 * -48.5x
Enterprise Value 6.71B 5.89B 5.5B 5.05B 9.45B 642B 9.68B 65.24B 25.51B 318B 25.18B 24.64B 1,099B EV / Sales 2026 *
677x
EV / Sales 2027 * 19.2x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day+2.20%
1 week-0.60%
Current month+3.36%
1 month+3.36%
3 months+11.76%
6 months+11.39%
Current year+12.61%
1 week 38.84
Extreme 38.84
41.17
1 month 37.04
Extreme 37.04
41.17
Current year 30.87
Extreme 30.87
41.35
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap.
7/1/26 A Free

Director

627 0.0004%
6/9/26 A Free

Director

17,901 0.0105%
6/9/26 A Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+3.06%-0.60%+246.92%+207.93% 6.76B
-3.43%-5.97%+43.23%+63.98% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
-0.37%+0.60%-15.85%-14.94% 23.51B
-3.30%-7.01%-5.04%+352.15% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.55%-3.94%+24.97%-34.37% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-0.47%-1.53%+48.69%+178.03% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.39%-1.14%+57.34%+164.99% 24.43B
Weighted average by Cap. -1.19%-0.50%+37.48%+126.02%

Financials

2026 *2027 *
Net sales 9.9M 8.7M 8.12M 7.45M 13.95M 949M 14.3M 96.32M 37.67M 469M 37.18M 36.37M 1.62B 349M 307M 286M 263M 492M 33.42B 504M 3.39B 1.33B 16.54B 1.31B 1.28B 57.17B
Net income -392M -344M -321M -295M -552M -37.5B -565M -3.81B -1.49B -18.56B -1.47B -1.44B -64.16B -132M -116M -108M -99.12M -186M -12.61B -190M -1.28B -501M -6.24B -494M -484M -21.58B
Net Debt -55.22M -48.52M -45.29M -41.56M -77.81M -5.29B -79.73M -537M -210M -2.62B -207M -203M -9.05B -63.88M -56.13M -52.39M -48.08M -90M -6.12B -92.22M -621M -243M -3.03B -240M -235M -10.47B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
30/07/26 $40.26 +1.73% 144,124
29/07/26 $39.57 -2.70% 1,220,992
28/07/26 $40.67 +0.57% 1,133,724
27/07/26 $40.44 +1.71% 1,383,712
24/07/26 $39.76 -1.19% 1,593,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
39.57USD
Average target price
54.25USD
Spread / Average Target
+37.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock